Comparison · NCT02874144-sae
AZ+INCS vs Placebo + INCS: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AZ+INCS vs Placebo + INCS: serious adverse events. Trial comparisons, record NCT02874144-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02874144-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0455 | 0.00807 | 0.218 | wilson | |
| Risk in group 2 | 0.0476 | 0.00846 | 0.227 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00216 | -0.185 | 0.175 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.955 | 0.0637 | 14.3 | log | |
| Odds ratio, group 1 over group 2 | 0.952 | 0.0557 | 16.3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on AZ+INCS than on Placebo + INCS | 462 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AZ+INCS | AZD1981 40 mg three times a day , added to 2 sprays daily of intranasal corticosteroid (INCS) spray for 12 weeks. | 1 | 22 | EG000 |
| Group 2 | Placebo + INCS | Matched Placebo (1:1 randomization) three times a day added to 2 sprays daily of intranasal corticosteroid (INCS) spray for 12 weeks | 1 | 21 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events were assessed every 2 weeks for the first month, then every 4 weeks for 12 weeks and during a 4 week washout period, an average of 5 months.
Source ClinicalTrials.gov
Trial
- Title
- Anti-Inflammatory Agent in Sinusitis
- NCT number
- NCT02874144
- Phases
- PHASE2
- Conditions
- Nasal Polyps
- Interventions
- AZ compound, Collection of Biological Specimens, Intranasal corticosteroid, Placebo
- Lead sponsor
- Northwestern University
- Results first posted
- 2022-05-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02874144?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02874144-sae